In Segment C, members will acquire ABBV-744 and oral navitoclax. In Phase D, individuals will receive ABBV-744 and ruxolitinib. Participants will receive treatment right until illness progression or even the participants are unable to tolerate the study drugs. Ubiquitin-linked proteins that regulate The soundness of crucial super enhancer-mediated proteins have https://marcelled443rco6.wikimillions.com/user